摘要
目的:评价醋酸曲安奈德局部注射对变应性鼻炎患者血清白介素4(interleukin-4,IL-4)和γ干扰素(interferon-γ,INF-γ)表达水平的影响。方法:60例变应性鼻炎患者随机分成观察组和对照组各30例,对照组予盐酸西替利嗪片10 mg,po,qd,观察组患者双侧中、下鼻甲黏膜下局部注射醋酸曲安奈德治疗。治疗4周后,检测两组患者血清IL-4、IFN-γ水平,比较两组疗效和药品不良反应。结果:观察组总有效率为93.33%,高于对照组的73.33%,但差异无统计学意义(P>0.05)。治疗4周后,观察组IL-4浓度低于对照组(P<0.01),IFN-γ浓度高于对照组(P<0.01)。两组均未发现不能耐受的不良反应或严重不良反应。结论:醋酸曲安奈德局部注射治疗变应性鼻炎疗效较佳,能够降低患者血清IL-4水平,并提高血清IFN-γ水平。
Objective: To evaluate the effect of local injection of triamcinolone acetonide on serum levels of interleukin 4 (IL-4) and interferon- γ( INF- γ) in the patients with allergic rhinitis. Methods: Totally 60 cases of allergic rhinitis patients were randomly di- vided into the observation group and the control group. The control group was given cetirizine hydrochloride tablets orally and the obser- vation group was with local injection of triamcinolone acetonide acetate in the nasal mueosa of middle and inferior nasal coneha. The ex- pression of IL-4 and IFN-γwere determined by enzyme-linked immunoadsorbent assay (ELISA) after the 4-week treatment. Results : After the 4-week treatment,the total effective rate was 93.33% in the observation group and 73.33% in the control group, however, the difference was not statistically significant(P 〉 0.05 ). IL-4 concentration of the observation group was (36.37 ± 8.32) pg · m1-1, which was lower than that of the control group (49.26 ± 8.68) pg ·m1-1 ,and IFN- γ concentration was (57.21 ± 10.34) pg · ml -1, which was higher than that of the control group (46.62 ± 8.25 ) pg · m1-1, and both were with statistically significant difference (P 〈 0. 01 ). No adverse drug reaction was observed in both groups. Conclusion: Local injection of triamcinolone acetonide acetate in trea- ting allergic rhinitis has better effect through controlling and decreasing the serum level of IL-4 and increasing the serum level of IFN-γ.
出处
《中国药师》
CAS
2014年第8期1371-1373,共3页
China Pharmacist
关键词
醋酸曲安奈德
局部注射
盐酸西替利嗪
变应性鼻炎
血白介素4
Γ干扰素
Triamcinolone acetonide acetate
Local injection
Cetirizine hydrochloride tablets
Allergic rhinitis
Interleukin-4
Interferon-γ